Citius Pharmaceuticals (CTXR) Competitors

Alterity Therapeutics (NASDAQ:ATHE) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their community ranking, earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends, media sentiment and risk.

Does the media refer more to ATHE or CTXR?

In the previous week, Alterity Therapeutics had 3 more articles in the media than Citius Pharmaceuticals. MarketBeat recorded 4 mentions for Alterity Therapeutics and 1 mentions for Citius Pharmaceuticals. Citius Pharmaceuticals' average media sentiment score of 1.89 beat Alterity Therapeutics' score of 0.22 indicating that Citius Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Alterity Therapeutics	Neutral
Citius Pharmaceuticals	Very Positive

Which has more risk and volatility, ATHE or CTXR?

Alterity Therapeutics has a beta of 0.71, meaning that its share price is 29% less volatile than the S&P 500. Comparatively, Citius Pharmaceuticals has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500.

Do institutionals & insiders believe in ATHE or CTXR?

2.1% of Alterity Therapeutics shares are held by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are held by institutional investors. 38.8% of Alterity Therapeutics shares are held by company insiders. Comparatively, 12.1% of Citius Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Does the MarketBeat Community prefer ATHE or CTXR?

Citius Pharmaceuticals received 207 more outperform votes than Alterity Therapeutics when rated by MarketBeat users. Likewise, 62.54% of users gave Citius Pharmaceuticals an outperform vote while only 62.50% of users gave Alterity Therapeutics an outperform vote.

Company	Underperform	Outperform
Alterity Therapeutics	Outperform Votes 5 62.50%	Underperform Votes 3 37.50%
Citius Pharmaceuticals	Outperform Votes 212 62.54%	Underperform Votes 127 37.46%

Which has stronger earnings & valuation, ATHE or CTXR?

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alterity Therapeutics	N/A	N/A	-$12.54M	N/A	N/A
Citius Pharmaceuticals	N/A	N/A	-$39.14M	N/A	N/A

Is ATHE or CTXR more profitable?

Alterity Therapeutics' return on equity of 0.00% beat Citius Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alterity Therapeutics	N/A	N/A	N/A
Citius Pharmaceuticals	N/A	-51.69%	-37.60%

Do analysts prefer ATHE or CTXR?

Alterity Therapeutics presently has a consensus price target of $12.00, suggesting a potential upside of 251.80%. Citius Pharmaceuticals has a consensus price target of $54.50, suggesting a potential upside of 7,335.20%. Given Citius Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Citius Pharmaceuticals is more favorable than Alterity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alterity Therapeutics	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Citius Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.33

Summary

Citius Pharmaceuticals beats Alterity Therapeutics on 9 of the 14 factors compared between the two stocks.